Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (NYSE: JNJ) announced its intent to separate the company's Consumer Health business, creating a new publicly traded company. These are the details.

Johnson & Johnson (JNJ) Splitting Into Two Publicly Traded Companies

On Friday, Johnson & Johnson (NYSE:JNJ) shares edged higher 1.44% amid reports the healthcare company plans to split into two. According to Wall Street Journal, JNJ wants to separate its drugs and medical devices business from the consumer products group, forming two publicly listed companies.

Johnson & Johnson stock forecast amid reports it plans to split into two

Johnson & Johnson is the latest in a line of mega-cap household names that have split their businesses in the name of focusing on growth

J&J's Corporate Split: Just Another Big, Blue-Chip Breakup

Healthcare conglomerate Johnson & Johnson is spinning off its consumer health division that sells Listerine and Baby Powder, to focus on the more-profitable pharmaceutical and medical device market.

Reactions to J&J's plans to split into two companies

Johnson & Johnson (NYSE: JNJ) announced that it was planning to separate its medical devices and pharma operations from its consumer products segment. This move will essentially create two separates publicly trading companies.

Johnson & Johnson plans to separate its pharmaceutical and consumer products business operations

Johnson & Johnson will divide into two public companies: one focused on consumer products and the other on pharmaceuticals and medical devices.

Johnson & Johnson (JNJ) Splitting Into Two Companies

Johnson & Johnson (NYSE: JNJ) is splitting up into two separate publicly traded companies, one focused on pharmaceutical and medical devices and the other on consumer products. Which of the two will attract more investors?

J&J to split up into two: what's next for the stock?

Pre-Markets Edge Up on JNJ Split News

In order to focus on market growth in its Pharma division, Johnson & Johnson now plans to split its Consumer Health business into a separate entity.

J&J Plans to Split in Two; Dow Up Triple Digits

Johnson & Johnson (NYSE:JNJ) is up 1.5% to trade at $165.43 at last check, after it announced it will split into two different companies that will each oversee its consumer goods and pharmaceutical businesses.

Johnson & Johnson Stock Moves Higher on Company Split News

Johnson & Johnson on Friday said it would split into two companies, hiving off its consumer health division that sells Band-Aids and Baby Powder from its pharmaceuticals and medical devices business.

Factbox-J&J's legal strategy for Baby Powder, talc liability

Healthcare conglomerate Johnson & Johnson's will soon spin-off its consumer health division, giving up a part of the company that has been the core to its business and image for more than 130 years.

Factbox: Baby Powder to Band-Aid: Key facts on J&J's consumer health business

Johnson & Johnson (JNJ) stock is on the move Friday after the company announced split plans that would create two public companies. The post JNJ Split: 10 Things for Investors to Know About Johnson & Johnson's Breakup Plans appeared first on InvestorPlace.

JNJ Split: 10 Things for Investors to Know About Johnson & Johnson's Breakup Plans

General Electric

Johnson & Johnson will split off consumer brands division Following General Electric's lead.

JNJ Following GE's Lead: Is Breaking Up Really That Hard To Do?

Johnson & Johnson (NYSE: JNJ) will separate its Consumer Health business into a publicly-traded company to pursue more targeted business strategies and accelerate growth. Alex Gorsky will serve as Executive Chairman of Johnson & Johnson and transition the CEO role to Mr.

Johnson & Johnson To Spin Off Consumer Health Business: What You Need To Know

Johnson & Johnson, the world's largest health products company, is splitting up.

Johnson & Johnson is breaking up Band-Aids and pharmaceuticals

Johnson & Johnson plans to break itself up into two companies, separating its business, which makes Band-Aids, Tylenol and baby powder.

J&J to split into two companies, severing consumer business behind Band-Aids

Johnson & Johnson said it plans to spin out its pharmaceutical business from its consumer products division, which includes products like Baby Powder, Tylenol and Band-Aid bandages.

Johnson & Johnson Shares Jump In Premarket As Firm Plans To Split Into Two Separate Companies

Health-care conglomerate Johnson & Johnson announced plans Friday to split its consumer products business from its pharmaceutical and medical device operations, creating two publicly traded companies. The news sent shares higher in premarket trading.

Johnson & Johnson plans to split into two companies, separating consumer health business

It plans to break itself up into pharmaceutical and consumer products companies.

Johnson & Johnson Stock Jumps on Reports It Plans to Split In Two

Johnson & Johnson plans to break up into two companies, splitting off its consumer health division that sells Band-Aids and Baby Powder from its large pharmaceuticals unit, it said on Friday.

Johnson & Johnson plans to split into two companies

Johnson & Johnson shares JNJ, -0.74% jumped 3.6% in premarket trade Friday, after Chief Executive Alex Gorksy told the Wall Street Journal that the company plans to split into two companies, splitting off the consumer group from the prescription drugs and medical devices business. J&J will separate the consumer business in 18 to 24 months, he said, because its customers and markets have diverged so much from the rest of the business in recent years, including during the pandemic.

J&J plans to split into two public companies and separate consumer and drug businesses

NEW BRUNSWICK, N.J., Nov. 12, 2021 /PRNewswire/ -- Johnson & Johnson (the "Company") (NYSE: JNJ) today announced its intent to separate the Company's Consumer Health business, creating a new publicly traded company.

Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business

European Medicines Agency (EMA) recommended adding transverse myelitis, a rare type of spinal inflammation, as a side-effect of the Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine. Giving updates on the safety of all coronavirus shots, the EMA said it was assessing reports of capillary leak syndrome, a rare blood condition after Moderna Inc's (NASDAQ: MRNA) vaccine.

EU Lists Spinal Cord Inflammation Probable Side Effect Of JNJ's COVID-19 Shot: Reuters

NEW BRUNSWICK, N.J., Nov. 10, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) has entered into an agreement with the U.S. Government and Gavi, the Vaccine Alliance (Gavi), to enable access to its single-shot COVID-19 vaccine through a novel mechanism – the COVAX Humanitarian Buffer – that will serve to protect the world's most vulnerable people.

Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World's Most Vulnerable People through Novel Humanitarian Buffer

News for Johnson & Johnson Stock (JNJ)